Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• BradburyAROlopadeOIGenetic susceptibility to breast cancerRev Endocr Metab Disord20078325526717508290
   PubMed Web of Science ®Google Scholar
• WolffMSWestonABreast cancer risk and environmental exposuresEnviron Health Perspect19971058918969255576
   PubMed Web of Science ®Google Scholar
• HulkaBSMoormanPGBreast cancer: hormones and other risk factorsMaturitas2008611–2203213 discussion 21319434892
   PubMed Web of Science ®Google Scholar
• LevineAJp53, the cellular gatekeeper for growth and divisionCell19978833233319039259
   PubMed Web of Science ®Google Scholar
• MomandJZambettiGPOlsonDCGeorgeDLevineAJThe mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell1992697123712451535557
   PubMed Web of Science ®Google Scholar
• BartelFMeyeAWurlPAmplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcomaInt J Cancer20019516817511307150
   PubMed Web of Science ®Google Scholar
• BondGLHuWBondEEA single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humansCell2004119559160215550242
   PubMed Web of Science ®Google Scholar
• RayburnEZhangRHeJWangHMDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapyCurr Cancer Drug Targets20055274115720187
   PubMed Web of Science ®Google Scholar
• HuZJinGWangLChenFWangXShenHMDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studiesCancer Epidemiol Biomarkers Prev200716122717272318086778
   PubMed Web of Science ®Google Scholar
• MeninCScainiMDe SalvoGAssociation between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation statusJ Natl Cancer Inst20069828528816478747
   PubMed Web of Science ®Google Scholar
• OhmiyaNTaguchiAMabuchiNMDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosisJ Clin Oncol2006244434444016983111
   PubMed Web of Science ®Google Scholar
• YoonYJChangHYAhnSHMDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infectionCarcinogenesis20082961192119618390844
   PubMed Web of Science ®Google Scholar
• SchmidtMKReinckeSBroeksADo MDM2 SNP309 and TP53R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortiumCancer Res200767199584959017909070
   PubMed Web of Science ®Google Scholar
• FuQZhangGChenHZhengYChengJCurrent evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer riskTumour Biol20133463721372923912932
   PubMedGoogle Scholar
• BoersmaBJHoweTMGoodmanJEAssociation of breast cancer outcome with status of p53 and MDM2 SNP309J Natl Cancer Inst20069891191916818855
   PubMedGoogle Scholar
• CampbellIGEcclesDMChoongDYNo association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancerCancer Lett200624019519716239061
   PubMed Web of Science ®Google Scholar
• MillikanRCHeardKWinkelSNo association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or WhitesCancer Epidemiol Biomarkers Prev20061517517716434608
   PubMed Web of Science ®Google Scholar
• PetenkayaABozkurtBAkilli-OzturkOKayaHSGur-DedeogluBYulugIGLack of association between the MDM2-309 polymorphism and breast cancer riskAnticancer Res2006264975497717214373
   PubMed Web of Science ®Google Scholar
• WilkeningSBermejoJLBurwinkelBThe single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancerCancer Res200666264664816423991
   PubMed Web of Science ®Google Scholar
• MaHHuZZhaiXPolymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese populationCancer Lett200624026126716288830
   PubMed Web of Science ®Google Scholar
• WasielewskiMNagelJHBrekelmansCMDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signalingBreast Cancer Res Treat200710415315717080308
   PubMed Web of Science ®Google Scholar
• CoxDGDeerDGuoQThe p53 Arg 72 Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studiesCancer Causes Control200718662162517387621
   PubMed Web of Science ®Google Scholar
• LumSSChuaHWLiHMDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese populationCarcinogenesis200829475476118281248
   PubMed Web of Science ®Google Scholar
• SinghVRastogiNMathurNSinghKSinghMPAssociation of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian womenAnn Epidemiol2008181485717719241
   PubMed Web of Science ®Google Scholar
• PaulinFEO’NeillMMcGregorGMDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphismBMC Cancer2008828118828900
   PubMed Web of Science ®Google Scholar
• KrekacDBrozkovaKKnoflickovaDMDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer riskOncology2008741–2848718547962
   PubMed Web of Science ®Google Scholar
• YardenRIFriedmanEMetsuyanimSOlenderTBen-AsherEPapaMZMDM2 SNP309 accelerates breast and ovarian carci-nogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descentBreast Cancer Res Treat200811149750418026875
   PubMed Web of Science ®Google Scholar
• LangAPalmebäck WegmanPWingrenSThe significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancerOncol Rep200922357557919639206
   PubMed Web of Science ®Google Scholar
• SunYFLeuJDChenSMLinIFLeeYJResults based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancerBMC Cancer200991319144119
   PubMed Web of Science ®Google Scholar
• KohWPVan Den BergDJinAWangRYuanJMYuMCCombined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in SingaporeBreast Cancer Res Treat201113031011101921833626
   PubMed Web of Science ®Google Scholar
• LeuJDWangCYTsaiHYLinIFChenRCLeeYJInvolvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancerOncol Rep20112561755176321479369
   PubMed Web of Science ®Google Scholar
• KnappskogSBjørnslettMMyklebustLMThe MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in CaucasiansCancer Cell201119227328221316605
   PubMed Web of Science ®Google Scholar
• AlshatwiAAHasanTNShafiGAlsaifMAAl-HazzaniAAAlsaifAAA single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab populationFundam Clin Pharmacol201226343844321477265
   PubMed Web of Science ®Google Scholar
• RischNMerikangasKThe future of genetic studies of complex human diseasesScience1996273151615178801636
   PubMed Web of Science ®Google Scholar
• WilkeningSBermejoJLHemminkiKMDM2 SNP309 and cancer risk: a combined analysisCarcinogenesis2007282262226717827408
   PubMed Web of Science ®Google Scholar
• JiangOZhouRWuDLiuYWuWChengNCYP2E1 polymorphisms and colorectal cancer risk: a HuGE systematic review and meta-analysisTumor Biol20133412151224
   PubMed Web of Science ®Google Scholar
• WanYWuWYinZGuanPZhouBMDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysisBMC Cancer20111120821619694
   PubMed Web of Science ®Google Scholar
• WoXHanDSunHMDM2 SNP309 contributes to tumor susceptibility: a meta-analysisJ Genet Genomics201138834135021867960
   PubMed Web of Science ®Google Scholar
• BondGLHirshfieldKMKirchhoffTMDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent mannerCancer Res2006665104511016707433
   PubMed Web of Science ®Google Scholar
• ToyamaTZhangZNishioMAssociation of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patientsBreast Cancer Res200793R3417537232
   PubMed Web of Science ®Google Scholar
• ChrisantharRKnappskogSLøkkevikEPredictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxelPLoS One201164e1924921556366
   PubMed Web of Science ®Google Scholar
• MaYYGuanTPYaoHBThe MDM2 309 T.G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controlsPLoS One201381e5501923383041
   PubMed Web of Science ®Google Scholar
• EconomopoulosKPSergentanisTNDifferential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysisBreast Cancer Res Treat2010120121121619590949
   PubMed Web of Science ®Google Scholar
• LohmuellerKEBustamanteCDClarkAGThe effect of recent admixture on inference of ancient human population historyGenetics2010185261162220382834
   PubMed Web of Science ®Google Scholar